Back to Studies

P1085 / Human Papilloma Virus (HPV) Type-Specific Antibody

Duration of Human Papilloma Virus (HPV) Type-Specific Antibody After Administration of Quadrivalent HPV Vaccine to HIV-infected Children

Study Status

Concluded

DAIDS Number

10826

IND Number

non-IND study

Clinical Trials Link

Study Chair

NICHD Medical Officer

DAIDS Clinical Representative

Drug Co. Representative

Field Representative

Investigator

Laboratory Data Manager (LDM)

Laboratory Technologist

Medical Officer

Statistician

Virologist

Abstracts

Four-Year Persistence of Type-Specific Immunity After Administration of Quadrivalent Human Papillomavirus Vaccine to HIV-infected Children: Effect of a Fourth Dose

Conference

IVP 2017

Study

P1085

Authors

Alfred Saah, Myron J Levin, Sharon Huang, Anna-Barbara Moscicki, Lin-Ye Song, Jennifer S Read, William A Meyer, Kelly Richardson, AdrianaWeinberg for the IMPAACT P1085 Protocol Team